Clinical impact of serum prealbumin in pancreaticobiliary disease
- Author:
Young Mok PARK
1
;
Hyung Il SEO
;
Byeong Gwan NOH
;
Suk KIM
;
Seung Baek HONG
;
Nam Kyung LEE
;
Dong Uk KIM
;
Sung Yong HAN
Author Information
- Publication Type:1
- From: Korean Journal of Clinical Oncology 2022;18(2):61-65
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Although there are many studies on prealbumin in individual diseases such as malignant or inflammatory diseases, there are few comparative studies. This study aimed to compare the clinical differences between prealbumin levels in cholecystitis and pancreaticobiliary malignancies and investigate the clinical impact of low prealbumin levels in pancreaticobiliary malignancies.
Methods:From June 2021 to September 2021, 61 patients who had undergone surgery for various pancreaticobiliary diseases were enrolled in this study, and their clinicopathological data were retrospectively analyzed.
Results:Many elderly patients with malignant diseases had poor American Society of Anesthesiologists (ASA) scores, significantly lower albumin and prealbumin levels, and higher systemic immune inflammation indices. The low prealbumin group was older; had poorer ASA scores; and had significantly lower body mass index and hemoglobin and albumin levels and higher systemic immune inflammation indices than the normal prealbumin group. In malignant diseases, the low prealbumin group had significantly lower body mass index and hemoglobin levels and a tendency toward more advanced disease (lymph node and distant metastasis).
Conclusion:Preoperative low prealbumin levels had an area under the receiver operator characteristic curve of 0.69, suggesting that it may be useful for predicting pancreaticobiliary malignancies. Prealbumin levels were lower in malignant diseases, possibly related to poor nutritional status and systemic immune inflammation. Low prealbumin levels may predict the risk of more advanced disease.
